| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11696396 | IVTH | 0.0000001 - 0.001 M | 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:12210538 | IVTH | 0.000000001 - 0.0001 M | 0.00001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVR | 1.2 mg | 1.2 mg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 - 0.0001 M | 0.000001 - 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 12 mg | 12 mg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:15721882 | IVR | 250 mg/kg/day | 250 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg/day | - | No significant effects observed | - | |
| IVR | 625 mg/kg/day | 625 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:19654335 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 1000 mg/kg/day | 1000 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 62.5 mg/kg/day | 62.5 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:19721353 | IVR | 4.36 mg/L/day | 4.36 mg/L/day | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations |
| IVR | 4.36 mg/L/day | 4.36 mg/L/day | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 4.36 mg/L/day | 4.36 mg/L/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:20132880 | IVR | 250 mg/kg | 250 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations |
| IVR | 250 mg/kg | 250 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 62.5 mg/kg | 62.5 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 62.5 mg/kg | 62.5 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 62.5 mg/kg | 62.5 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:29945225 | IVTH | 0.00001 M | 0.00001 M | Affects estrogen signaling | Reproductive endocrine-mediated perturbations |
| PMID:35810903 | IVTH | 0.000001 - 0.00005 M | 0.000001 - 0.00005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:38619594 | IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations |
| IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 2 - 5 mg/kg/day | 2 - 5 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.